Washington, D.C. 20549







Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): April 11, 2018



Vaxart, Inc.

(Exact name of registrant as specified in its charter)




Delaware   001-35285   59-1212264

(State or other jurisdiction

of incorporation)



File Number)


(IRS Employer

Identification No.)

290 Utah Ave. Suite 200

South San Francisco, California

(Address of principal executive offices)   (Zip Code)

Registrant’s telephone number, including area code: (650) 550-3500



Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:


Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)


Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)


Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))


Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging Growth Company  ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐




Item 5.07. Submission of Matters to a Vote of Security Holders.

On April 11, 2018, Vaxart, Inc. held its 2018 Annual Meeting of Stockholders, or the 2018 Annual Meeting, at 395 Oyster Point Boulevard, South San Francisco, California 94080. At the 2018 Annual Meeting, our stockholders voted on three proposals, each of which is described in more detail in our definitive proxy statement on Schedule 14A filed with the U.S. Securities and Exchange Commission on February 26, 2018. The following is a brief description of each matter voted upon and the results, including the number of votes cast for and against each matter and, if applicable, the number of abstentions and broker non-votes with respect to each matter. Proxies for the 2018 Annual Meeting were solicited pursuant to Section 14(a) of the Securities Exchange Act of 1934, as amended, and there was no solicitation in opposition of management’s solicitation.

Proposal 1. Stockholders elected the seven nominees for directors to serve until Vaxart’s 2019 Annual Meeting of Stockholders or until his or her respective successor has been duly elected and qualified. The voting results were as follows:


Director Name

   Votes For      Votes Withheld      Broker Non-Votes  

Wouter Latour, M.D.

     3,387,650        22,074        408,663  

Geoffrey F. Cox, Ph.D.

     3,387,478        21,933        408,663  

Michael J. Finney, Ph.D.

     3,387,802        21,922        408,663  

Jan Leschly

     3,382,280        27,444        408,663  

Richard J. Markham

     3,382,231        27,493        408,663  

John P. Richard

     3,387,478        22,246        408,663  

Anne M. VanLent

     3,387,524        22,200        408,663  

Proposal 2. Stockholders ratified the selection by the Audit Committee of the Board of Directors of Vaxart of KPMG LLP as Vaxart’s independent registered public accounting firm for the year ending December 31, 2018. The voting results were as follows:


Votes For


Votes Against




Broker Non-



   31,072    1,091   

Proposal 3. Stockholders approved, on an advisory basis, the compensation of the former Aviragen Therapeutics, Inc. named executive officers. The voting results were as follows:


Votes For


Votes Against




Broker Non-



   54,160    173,441    408,663


Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


    Vaxart, Inc.
Dated: April 11, 2018    

/s/ Wouter Latour

      Wouter Latour, M.D.
      President and Chief Executive Officer